多細胞血症 の 診断 と 治療: レビュー
Douglas Tremblay1, Marina Kremyanskaya1, John Mascarenhas1
1Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
JAMA
|November 18, 2024
まとめ
多細胞血症 (PV) は,赤血球を増やす血液がんであり,血栓形成の危険性があります. 治療にはフレボトミー,アスピリン,高リスク患者の細胞減少療法が含まれます.
科学分野:
- 血液学
- 腫瘍学
- 遺伝学
背景:
- 多細胞血症 (PV) は,赤血球症によって定義される骨髄増殖性腫瘍であり,米国では約65,000人に影響する.
- PV患者の95%以上がJAK2遺伝子変異を有し,二次性赤血球症と区別する.
- PVは,血栓形成,出血,骨髄繊維症,急性骨髄性白血病のリスクを増加させる.
研究 の 目的:
- ポリシテミア・ベラの主な特徴,診断,治療についてまとめます.
- JAK2変異とPVの関連性とその影響を強調する.
- 血栓の減少と症状の管理を目的とした現在の治療戦略を概説する.
主な方法:
- ヘモグロビン値や一般的な臨床的特徴を含む診断基準のレビュー
- PVを他の疾患と区別するために,JAK2変異の遺伝子検査を行う.
- フレボトミー,アスピリン,細胞縮小療法,標的薬を含む治療結果の分析
主要な成果:
- 赤血球症は診断の特徴であり,血栓細胞症と白血球症は頻繁に発生する.
- 常見の症状には, pruritus, erythromelalgia, 視力の変化,そして splenomegaly が含まれる.
- 平均生存期間は14. 1年から27. 6年の間であり,血栓形成は16%の動脈,7%の静脈で起こります.
- PV患者は,特に極端な血栓細胞症で,出血のリスクが増加します.
結論:
- 血栓形成のリスクを軽減するために,フレボトミーとアスピリンが必要です.
- 細胞減少療法 (ヒドロキシウレア,インターフェロン) は,高リスクの患者に用いる.
- ルクソリチニブのような標的治療は,耐性または不耐性の症例の選択肢を提供します.
- 長期的な合併症には 骨髄繊維症と急性骨髄性白血病が含まれます
関連する概念動画
Disorders of Erythrocytes
863
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
863
Esophageal Varices-II: Clinical Features and Management
46
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
46
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
141
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
141
Increased pulse rate
646
Tachycardia is a condition marked by an abnormally fast or irregular heart rate, surpassing the typical resting rate. In adults, tachycardia is characterized by a pulse rate ranging from 100 to 180 beats per minute. The increased heart rate can result in inadequate blood flow to various body parts, ultimately diminishing the oxygen supply to organs and tissues.
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
646
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
175
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
175
Erythropoiesis
4.1K
Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia,...
4.1K


